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Abstract
Background Rhythm control for atrial fibrillation (AF) is
cumbersome because of its progressive nature caused by
structural remodelling. Upstream therapy refers to therapeu-
tic interventions aiming to modify the atrial substrate, lead-
ing to prevention of AF.
Objective The Routine versus Aggressive upstream rhythm
Control for prevention of Early AF in heart failure (RACE
3) study hypothesises that aggressive upstream rhythm con-
trol increases persistence of sinus rhythm compared with
conventional rhythm control in patients with early AF and
mild-to-moderate early systolic or diastolic heart failure
undergoing electrical cardioversion.
Design RACE 3 is a prospective, randomised, open, multi-
national, multicenter trial. Upstream rhythm control consists
of angiotensin converting enzyme inhibitors and/or
angiotensin receptor blockers, mineralocorticoid receptor
antagonists, statins, cardiac rehabilitation therapy, and
intensive counselling on dietary restrictions, exercise main-
tenance, and drug adherence. Conventional rhythm control
consists of routine rhythm control therapy without cardiac
rehabilitation therapy and intensive counselling. In both
arms, every effort is made to keep patients in the rhythm
control strategy, and ion channel antiarrhythmic drugs
or pulmonary vein ablation may be instituted if AF
relapses. Total inclusion will be 250 patients. If upstream
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therapy proves to be effective in improving maintenance of
sinus rhythm, it could become a new approach to rhythm
control supporting conventional pharmacological and non-
pharmacological rhythm control.
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Background and rationale
Atrial fibrillation (AF) is the most common cardiac arrhyth-
mia, currently affecting more than six million people in
Europe. The prevalence of AF is expected to increase twofold
during the next 30–50 years, partly due to the ageing popula-
tion and lifestyle changes [1]. AF is responsible for an in-
creased risk of death, stroke, heart failure, hospitalisation, and
an impaired quality of life. In order to improve outcome and to
promote healthy ageing, it is important to develop safe and
effective treatment strategies. Rhythm control is the therapeu-
tic strategy of choice in patients who have symptomatic AF
[2]. However, AF is difficult to treat because of the progres-
sive nature of the arrhythmia.
Structural remodelling seems to play an important role in
the initiation and maintenance of AF. It can be caused by
risk factors for AF including increasing age, underlying
diseases and other factors such as altered metabolism, auto-
nomic changes, and genetic and environmental influences [3].
These factors induce atrial structural changes through various
pathways including the renin-angiotensin-aldosterone system
(RAAS) and inflammation, leading to enlarged atria, hyper-
trophy, fibrosis, and myolysis [4–6]. Structural remodelling
creates a substrate for AF as a result of electrical dissociation
between muscle bundles and local conduction heterogeneities
facilitating the initiation and perpetuation of AF [5, 6]. Indeed,
the first manifestation of AF usually occurs after years of atrial
and ventricular remodelling [7, 8]. Once AF develops, it
causes marked changes in atrial electrophysiology (‘electrical
remodelling’) and the structural remodelling process further
deteriorates, constituting a vicious cycle in which ‘AF begets
AF’ [5, 6, 9], making it challenging to restore and maintain
sinus rhythm (Fig. 1) [7].
Outcome of current rhythm-control therapies is often
poor because of progressive structural remodelling and
limitations in efficacy and adverse events of the available ion-
channel antiarrhythmic drugs and ablation techniques.
Ablation and ion-channel antiarrhythmic drugs counteract
electrical remodelling processes, but do not alter the underly-
ing structural remodelling.
Upstream therapy refers to the use of non-ion-channel
antiarrhythmic drugs that modify the atrial substrate to prevent
the occurrence of new-onset AF (i.e., primary prevention) or
recurrence of AF (i.e., secondary prevention). It includes
treatment with RAAS blockers (angiotensin-converting-en-
zyme inhibitors [ACEIs], angiotensin-receptor blockers
[ARBs], and mineralocorticoid receptor antagonists
[MRAs]), and statins (Fig. 1) [10]. RAAS blockers may
prevent or reduce atrial structural remodelling by decreas-
ing fibrosis and by improving haemodynamics through
lowering of blood pressure and reduction of ventricular
and atrial wall stress [11–13]. RAAS blockers may also
prevent AF by counteracting the effects of aldosterone
on potassium channels leading to shortening of the
action potential [14]. Statins, known for their lipid-
lowering capacities, have pleiotropic properties such as re-
duction of inflammation and oxidative stress. Through these
properties, statins may play a protective role against the de-
velopment of AF [11, 15–17]. Moderate exercise may also
reduce AF by targeting structural remodelling. Moderate
physical activity is associated with a significantly lower inci-
dence of AF [18–20]. In addition, peak oxygen consumption
increases by 20 %, left ventricular remodelling may reverse,
and diastolic function may improve [21, 22].
Upstream therapy may improve the outcome of rhythm-
control therapy and could prevent or postpone the need for
ion-channel antiarrhythmic drugs and/or ablation, while
having fewer adverse events. Results of upstream therapy
for the prevention of AF in animal experiments, hypothesis-
generating small clinical studies, and retrospective analyses
in selected patient categories have been encouraging
[23–26]. ACEIs and ARBs seem to be beneficial in second-
ary AF prevention especially when atrial remodelling is less
advanced, and when added to amiodarone [27]. On the other
hand, other trials did not show any beneficial effect for
secondary prevention [28, 29]. MRAs may be even more
effective in preventing AF recurrences but only few data are
available [30]. Results regarding effectiveness of statins in
preventing AF recurrences have been inconclusive [31–33].
Overall, upstream therapy seems to be most effective in
primary prevention. The disappointing results regarding
secondary AF prevention may have been caused by inclu-
sion of patients in whom the extent of remodelling was too
severe and irreversible due to a long history of AF and
underlying heart disease [34, 35]. Inclusion of patients in
whom remodelling processes are less advanced, i.e. patients
with a short history of both AF and underlying heart disease,
may improve outcome. These patients have not been studied
before. In addition, the institution of several types of up-
stream therapies instead of just one type of upstream therapy
may improve success. In heart failure, upstream therapy can
further reduce AF through reduction or reversion of ventric-
ular remodelling. Reversal of heart failure has been shown
to be followed by normalised atrial function and decreased
duration of AF, though not all substrate for AF [36].
Therefore, upstream therapies may be most effective in AF
that occurs in patients with heart failure [37].
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The Routine versus Aggressive upstream rhythm Control
for prevention of Early atrial fibrillation in heart failure
(RACE 3) study tests the hypothesis that aggressive up-
stream rhythm control increases persistence of sinus rhythm
in patients with short-lasting (i.e., early) AF and mild-to-
moderate early systolic or diastolic heart failure. Aggressive
upstream rhythm control consists of a combination of non-
ion-channel antiarrhythmic drugs (ACEIs and/or ARBs,
MRAs, and statins), cardiac rehabilitation therapy, counsel-
ling and dietary restrictions in addition to conventional heart
failure drugs. We postulate that the institution of a combi-
nation of different classes of upstream therapy may have
synergistic effects on the atrial substrate by decreasing AF
directly through reduction of atrial remodelling and indirectly
through reduction of ventricular remodelling (Fig. 1). This
may ultimately enhance persistence of sinus rhythm and
possibly also improve prognosis [35].
Study design and methods
Study oversight
TheRACE3 study (ClinicalTrials.gov Identifier NCT00877643)
is a prospective, randomised, open-label, multinational,
multicenter, superiority trial designed to compare two
rhythm-control strategies in patients with short-lasting
(i.e. early) persistent AF. The study is initiated and coordinat-
ed by the Interuniversity Cardiology Institute of the
Netherlands, the University Medical Center Groningen, and
the Working Group on Cardiovascular Research the
Netherlands. The trial is funded by major grants from the
Netherlands Heart Foundation (NHS B 2008 035), the
Interuniversity Cardiology Institute Netherlands and the
Working Group on Cardiovascular Research the Netherlands
and by unrestricted educational grants from pharmaceutical
and device companies. None of the sponsors are involved in
the study design and data collection, data analysis, or manu-
script preparation. The steering committee (see Appendix)
designed the study and is responsible for the conduct of the
study, data analyses and reporting, and manuscript prepara-
tion. Study monitoring, data management and validation are
independently performed at the Trial Coordination Center
(University Medical Center Groningen, the Netherlands).
The study was approved by the institutional review boards
of all participating centers. All patients are asked to give
written informed consent.
Study recruitment started in 2009, and randomisation is
expected to be concluded in the summer of 2014. Follow-up
for the primary endpoint will be 1 year. In addition, an
exploratory randomised long-term extension of the RACE
3 study will be performed to study the long-term effects of
Fig. 1 Time course of atrial substrate remodelling starting long before
the first episode of atrial fibrillation (AF): hypothetical representation
of how underlying disease such as hypertension or heart failure induces
atrial remodelling long before the onset of AF and of how atrial
remodelling progresses in relation to the clinical appearance of AF.
The light grey arrow denotes early institution of upstream therapy in
persistent AF, which may reduce or reverse atrial remodelling (dotted
line) and could improve maintenance of sinus rhythm. ACEI angioten-
sin converting enzyme inhibitor, MRA mineralocorticoid receptor
antagonist, ARB angiotensin-receptor blocker, ECV electrical car-
dioversion, SR sinus rhythm. Adapted with permission from Cosio
et al. [7]
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the two treatment strategies. Total follow-up will be 5 years.
The study is being conducted in 15 centers in the
Netherlands and five centers in the United Kingdom. At
present, 168 patients have been included.
Objectives
The primary objective is to investigate whether in patients
with early AF and mild-to-moderate early systolic or dia-
stolic heart failure an aggressive upstream rhythm-control
approach, including ACEIs and/or ARBs, MRAs, statins,
cardiac rehabilitation therapy, counselling, and dietary re-
strictions, increases persistence of sinus rhythm compared
with conventional rhythm control.
Secondary objectives will investigate whether aggressive
upstream rhythm control improves persistence of sinus
rhythm without the need for class III ion-channel antiar-
rhythmic drugs or pulmonary vein ablation, quality of life,
left ventricular function, and exercise capacity, and de-
creases the number of patients with permanent AF, number
of electrical cardioversions, numbers of pulmonary vein and
atrioventricular node ablations, hospitalisations for heart
failure or other cardiovascular reasons, and all-cause mor-
tality. Cost-effectiveness will also be studied. In addition,
the association of biomarkers of processes related to
remodelling and thrombosis, and the role of genetic factors
in AF recurrences, the development of heart failure
hospitalisations and other cardiovascular morbidity and
mortality will be investigated.
Study population
The study population consists of patients with early symp-
tomatic persistent AF and mild-to-moderate early heart fail-
ure who are to undergo an electrical cardioversion and who
are otherwise stable. A total of 250 patients are to be
included. Early symptomatic persistent AF is defined as a
total history of AF <5 years before randomisation and a total
persistent AF duration of >7 days but <6 months (more than
one episode is allowed), with a maximum of one previous
electrical cardioversion during the last 2 years; neither elec-
trical nor chemical cardioversion ≥2 years ago are allowed.
Mild-to-moderate early heart failure is defined as a total
heart failure history <1 year and either diastolic heart failure
(left ventricular ejection fraction [LVEF] ≥45 %, New York
Heart Association [NYHA] functional class II-III, and addi-
tional criteria consisting of echo parameters and/or elevated
N-terminal pro-brain natriuretic peptide [NTproBNP]), or
systolic heart failure (LVEF 25–45 % and NYHA class I–
III). The most important exclusion criteria include severe heart
failure, i.e. NYHA class IV or LVEF <25 %, left atrial size
>50 mm, severe valvular disease, and present MRA use. A list
of inclusion and exclusion criteria is provided in Table 1.
Randomisation and treatment
Patients are randomised to either aggressive upstream rhythm
control or conventional rhythm control. Randomisation is
performed 3 weeks prior to electrical cardioversion in order
to start upstream therapy 3 weeks before cardioversion
(Fig. 2).
Aggressive upstream rhythm control consists of: 1)
Rhythm control for AF including electrical cardioversion
and antiarrhythmic treatment as in routine clinical practice,
according to the guidelines [2, 38]. The first ECV will be
performed without institution of class III ion-channel anti-
arrhythmic drugs but with a beta-blocker. In addition, pa-
tients are started on upstream medication to prevent AF (i.e.
ACEIs and/or ARBs, and MRAs, and statins); 2) Optimal
medication for heart failure according to the guidelines; 3)
Dietary (salt and fluid) restrictions; 4) Counselling by heart
failure/rhythm nurse (visits every 6 weeks); and 5) Cardiac
rehabilitation. Treatment with upstream therapy is started at
randomisation and continued during follow-up. Every effort
is made to titrate each patient to the highest dose free from
unacceptable side effects for all upstream drugs.
Counselling by the heart failure/rhythm nurse is performed
every 6 weeks to check and stimulate physical activity and
drug adherence and to make patients aware of dietary factors
that can reduce disease burden. Heart rhythm is assessed on
ECG. Furthermore, patients will be stimulated to quit
smoking. Cardiac rehabilitation aims to stimulate patients
to be physically active. Cardiac rehabilitation starts imme-
diately after inclusion and lasts 9–11 weeks (at least 6–
8 weeks after electrical cardioversion, even if cardioversion
needs to be postponed). Supervised physical training takes
place at least two, but preferably three times a week.
Training is performed according to perceived exertion, in
which patients are stimulated to exercise at the highest pace
or intensity that still allows for comfortable conversation.
Conventional rhythm control consists of: 1) Rhythm con-
trol for AF including electrical cardioversion and antiarrhyth-
mic treatment as in routine clinical practice, according to the
guidelines [2, 38]. The first ECV will be performed without
institution of class III ion-channel antiarrhythmic drugs but
with a beta-blocker; 2) Optimal medication for heart failure
according to the guidelines; 3) Follow-up visits (without
counselling) every 6 weeks for documentation of heart rhythm
with ECG only.
The difference between upstream rhythm control and
conventional rhythm control consists of the aggressive in-
stitution of upstream drugs (ACEIs and/or ARBs, and
MRAs, and statins), dietary restrictions, counselling visits,
and cardiac rehabilitation.
Background therapy in both treatment arms: In both
treatment arms re-electrical cardioversion is performed after
a recurrence with institution of ion-channel antiarrhythmic
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drugs and/or pulmonary vein ablation according to the
guidelines [2].
Follow-up
Follow-up visits take place at one, three, six, nine, and
12 months after the first study electrical cardioversion.
Thereafter in the long-term extension, patient visits are
twice a year in the aggressive group, alternated with tele-
phone counselling by the research nurse every 6 months
between the visits, and once a year in the conventional
group. Total follow-up will be 5 years. A blood sample for
biomarker and genetic analyses, 24-h urine to assess sodium
secretion, echocardiogram, bicycle exercise testing and
questionnaires testing quality of life and costs are collected
at baseline and at 1 year of follow-up. During follow-up in
both treatment arms every effort is made to keep the patient
in a rhythm-control strategy. An electrocardiogram is
conducted every 6 weeks to aid documentation of recurrent
AF. Recurrence of persistent AF is defined as documented,
symptomatic AF episodes lasting longer than 7 days or that
do not terminate spontaneously. The persistence of AF is
preferably verified by 24-h Holter monitoring to show
continuous (and not paroxysmal) AF. Cardiovascular
hospitalisations and mortality are carefully documented and
monitored. A committee of experts who are unaware of
the treatment assignments will adjudicate cardiovascular
morbidity and mortality.
Definitions
Permanent AF is defined as accepted AF [2]. Hospitalisation
for heart failure is defined as a hospitalisation (≥1 overnight
stay) for heart failure requiring intravenous diuretics. Stroke
Table 1 Inclusion and exclusion criteria for the RACE 3 study
Inclusion criteria Exclusion criteria
- Early symptomatic persistent AF defined as: - Symptoms not allowing electrical cardioversion to be delayed
for 3 weeks1. Total AF history <5 years, and
- Heart failure NYHA functional class IV2. Total persistent AF duration >7 days and <6 months, and
- LVEF <25 %3. ≤ 1 previous electrical cardioversion during the last
2 years; neither electrical nor chemical cardioversion
≥2 years ago are allowed.
- Left atrial size >50 mm (parasternal axis)
- Mild-to-moderate early heart failure, defined as:
- Severe valvular disease (previous valve repair/replacement is permitted)
1. Total heart failure history <1 year, and
- Present MRA use
2. One of the following:
- Patients with cardiac resynchronisation therapy
- LVEF ≥45 % and NYHA II-III, and normal pulmonary
function and body mass index <40 kg/m2, and
- Previous use of continuous prophylactic class I
or class III antiarrhythmic drugs
- Previously documented heart failure-related NT-proBNP
elevation (> 400 ng/l (= 48 pmol/l)), or
- Postoperative AF
- Evidence of structural heart disease including left
ventricular hypertrophy (posterior wall and/or septum
diameter ≥11 mm or ≥10 mm using Penn’s method) or
regional left ventricular dysfunction (akinesia, hypokinesia), or
- Myocardial infarction within last 3 months
- Previous admission for heart failure, or
- Hypersensitivity against MRAs
- Evidence of diastolic dysfunction on echocardiography
(average annular e’ <8 cm/s, and deceleration time >220 ms,
and average E/e’ >8 or in case of colour coded TDI E/e’ >11)
- Uncontrolled hypertension (systolic blood pressure >160 mmHg
and/or a diastolic blood pressure >95 mmHg
- LVEF 25–45 % and NYHA class I–III
- Unstable angina pectoris
- Optimal documentation and treatment of underlying heart disease
- Open heart surgery within the last 3 months
- Otherwise stable patients
- Serum potassium >5 mmol/l
- No contraindication for oral anticoagulation
- Acute and reversible illnesses
- Eligible for cardiovascular rehabilitation program
- Alcohol or drug abuse or a severe progressive extracardiac disease
- Age ≥40 years
- Untreated manifest and latent hyper- or hypothyroidism
or <3 months euthyroidism
- Moderate to severe renal insufficiency
(creatinine clearance less than 50 ml/min)
- Patients with liver cirrhosis (Child-Pugh class C) or repeated
ALAT/ASAT 1.5 times the upper limit or other significant liver disease
- Co-administration of strong CYP3A4 inhibitors (i.e. grapefruit juice,
ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin,
erythromycin, telithromycin, indinavir, nelfinavir, ritonavir, saquinavir,
HIV-protease inhibitors) or strong CYP3A4 inductors (i.e. carbamazepine,
rifampicin, St John’s Wort)
- Pregnancy
- Complex congenital heart diseases. The only congenital heart
diseases that can be included are atrial septal defect,
ventricular septal defect, bicuspid aortic stenosis
- Patients unlikely to comply with the protocol
AF atrial fibrillation, MRA mineralocorticoid receptor antagonist, LVEF left ventricular ejection fraction, NT-proBNP N-terminal related pro-B-type
natriuretic peptide, NYHA New York Heart Association
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is defined as a disabling haemorrhagic, ischaemic or
undetermined stroke confirmed by a neurologist on the basis
of computerised tomography or magnetic resonance imag-
ing and necessitating hospitalisation. Systemic emboli must
be confirmed by a physician and necessitate hospitalisation.
Bleeding is defined as bleeding with a decrease in the
haemoglobin value of >20 g/l or requiring blood transfu-
sion, or symptomatic bleeding in a critical organ or area
(intra-cranial, retroperitoneal, spinal, ocular, pericardial,
atraumatic articular), or as a fatal bleeding. Syncope is
defined as sudden temporary loss of consciousness with
spontaneous recovery accompanied by trauma necessitating
hospital admission (≥1 overnight stay). Life-threatening ad-
verse effects of antiarrhythmic drugs include drug-induced
heart failure, conduction disturbances and ventricular ar-
rhythmias necessitating hospital admission (≥1 overnight
stay). Myocardial infarction requires at least two of the
following: 1) typical chest pain for at least 20 min; 2)
electrocardiogram showing signs of acute myocardial in-
farction; 3) cardiac enzyme elevation more than twice the
upper limit of normal. Life-threatening arrhythmias are
defined as those arrhythmias requiring hospitalisation. All-
cause mortality is categorised by means of blinded adjudi-
cation into four categories: death from cardiac arrhythmia,
death from non-arrhythmic cardiac causes, death from non-
cardiac vascular causes, and death from non-cardiovascular
causes.
Endpoints
The presence of the primary endpoint requires that: 1) the
patient is still in a rhythm-control strategy according to the
attending physician, and 2) that sinus rhythm is maintained
after 1 year of follow-up, defined as sinus rhythm during
≥6/7th of the assessable time of continuous 7-day Holter
monitoring during the last week of the study. Failure to fulfil
these requirements is considered therapy failure. The prima-
ry endpoint therefore requires that a 7-day Holter is
performed during the last 7 days of follow-up. At least
5/7th of the continuous 7-day Holter monitoring should be
assessable; otherwise, the 7-day Holter monitoring is to be
repeated.
Fig. 2 Flowchart of the RACE
3 study schedule
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Secondary endpoints include: 1) The presence of sinus
rhythm during 7-day Holter monitoring after 1 year of
follow-up with or without antiarrhythmic drugs; 2) Sinus
rhythm after 1 year of follow-up during 7-day Holter
monitoring without the need for pulmonary vein isolation;
3) Permanent AF; 4) Number of electrical cardioversions;
5) Pulmonary vein ablations; 6) Atrioventricular node
ablation; 7) Left ventricular systolic and diastolic func-
tion; 8) Exercise capacity; 9) Hospitalisations for heart
failure; 10) Hospitalisations for other cardiovascular rea-
sons and 11) All-cause mortality. Additional analyses
include quality of life, biomarker and genetic analyses
and costs and cost-effectiveness assessment. Quality of
life assessment includes the Short Form Health Survey
(SF)-36, Multidimensional Fatigue Index (MVI)-20,
Eysenck Personality Questionnaire (EPQ), Toronto AF
Questionnaire, Center for Epidemiologic Studies
Questionnaire (CES-D), Minnesota Questionnaire,
European Heart Failure Self-Care Behaviour Scale,
Hospital Anxiety and Depression Scale (HADS), and the
Ladder of Life. Biomarker analyses will include markers
associated with collagen metabolism, inflammation, de-
differentiation, thrombosis, neurohumoral factors and pro-
teomic profiles in order to study the association between
severity of remodelling, heart failure and activation of
thrombosis and outcome of AF. In addition, genetic anal-
yses will be performed. Costs will be calculated from a
societal perspective. All relevant costs inside and outside
the health care system are taken into account. Direct
medical costs, direct non-medical costs, and indirect
non-medical costs will be calculated. The time horizon
of the economic evaluation will be equal to that of the
clinical study. For the exploratory randomised long-term
extension all the above-mentioned endpoints will be
assessed as secondary endpoints after 5 years of follow-
up.
Electronic data collection
All data are recorded electronically and are transferred to the
server holding the central database at the Trial Coordination
Center, which is regularly backed up and password
protected. The electronic case record forms are monitored
at regular times by the study monitor.
Data safety monitoring board
A data safety monitoring board (DSMB) has been
established to perform on-going safety surveillance and to
perform interim analyses on the safety data, in addition to
assessing scientific content. The DSMB is an independent
committee that meets on a regular basis to evaluate (serious)
adverse events and clinical endpoints.
Endpoint adjudication committee
A committee of experts, masked to the treatment assign-
ments, will adjudicate all possible (clinical) endpoints.
Statistical considerations
The RACE 3 study is a superiority trial; the null hypothesis
(H0) is that the number of patients in sinus rhythm in the
upstream rhythm-control arm will be equal to the number of
patients in sinus rhythm in the conventional rhythm-control
arm. The alternative hypothesis (Ha) is that there will be
more patients in sinus rhythm in the upstream rhythm-
control arm than in the conventional rhythm-control arm.
To test these hypotheses, chi-square analysis and logistic
regression (univariate and multivariate) will be conducted.
The primary efficacy population (intent-to-treat) consists of
all randomised patients. Patients will be analysed according to
treatment received. The number of subjects who enrol and are
randomised will be summarised by treatment group. The
number of subjects withdrawing from the study will be tabu-
lated by reason for withdrawal and by treatment group. The
time of withdrawal and reason for withdrawal will be listed by
treatment group. Potential biases due to withdrawal of sub-
jects will be investigated. Patients’ demographics and disease
characteristics at baseline will be tabulated and evaluated for
treatment group differences. If differences are found, caution
will be taken when interpreting the results of the analyses
between groups and the methods may be modified to adjust
for these differences.
For quantitative parameters, descriptive statistics will be
mean, standard deviation, median, inter-quartile range and
range of minimum and maximum, and number of valid
observations by treatment group. Mean, median and inter-
quartile range will be reported to a precision of one or two
decimal places more than the individual measurements;
standard deviation will be reported to a precision of two
decimal places more than the individual measurements;
range will have the same precision as the individual mea-
surements. Appropriate statistics will be used to compare
treatment groups. In all statistical analyses, a two-sided p<
0.05 is considered statistically significant.
Unless stated otherwise, all secondary analyses will be
performed using the same patients included in the primary
analysis. Secondary variables will be analysed using an
appropriate statistical test, depending on the nature of the
variable. Changes in parameters over time in the different
treatment groups will be analysed using repeated measure-
ment analysis or techniques that evaluate the timing of
endpoints, when appropriate.
The sample size is based on data of other studies.
Persistence of sinus rhythm has been observed in 20 % to
50 % of patients 1 year after electrical cardioversion. These
360 Neth Heart J (2013) 21:354–363
numbers approach 20 % to 30 % when patients have a
history of heart failure [39–42]. In a treatment strategy using
electrical cardioversions and amiodarone, persistence of
sinus rhythm was observed in 50 % after 1 year of follow-
up [43]. Therefore, we expect that after 1 year of follow-up,
persistence of sinus rhythm will be observed in 50 % of
patients randomised to conventional rhythm control versus
70 % of patients randomised to upstream rhythm control.
Based on a type 1 error of 0.05 and a power of 80 %, we
calculated an estimated sample size of 100 patients in each
study group. Taking into account a dropout rate of 20 %, the
sample size should be 250 patients in total. Stratification is
done for LVEF< and ≥45 %. An interim analysis consisting
of a preliminary open assessment of the primary endpoint
will be conducted by an independent data monitoring com-
mittee after 100 patients have completed the protocol. This
will be done in order to have the option to adapt the sample
size if the incidence rates at the interim analyses of the two
treatment arms are different than originally expected to find
the predefined treatment effect.
Conclusion
Increasing knowledge concerning the structural remodelling
processes in the atria before and during AF at least in part
clarifies the failure of current rhythm-control therapies in AF.
Upstream therapy that prevents or attenuates the remodelling
process may be effective or at least support conventional
rhythm-control therapies in maintaining sinus rhythm, espe-
cially in patients in whom structural remodelling processes are
less advanced. The RACE 3 study is a randomised trial
investigating whether an aggressive upstream rhythm-control
approach, including ACEIs and/or ARBs, MRAs, statins,
cardiac rehabilitation therapy, counselling, and dietary restric-
tions, increases persistence of sinus rhythm compared with
conventional rhythm control. The study is conducted in pa-
tients with early persistent AF, in whom structural remodelling
processes are expected to be less advanced and in whom
upstream rhythm control may therefore be beneficial. If such
upstream therapy proves to be effective in improving mainte-
nance of sinus rhythm, it could become a new approach to
rhythm control, supporting conventional pharmacological and
non-pharmacological rhythm control.
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